Inclusion body myositis (IBM) progresses slowly compared to many other muscle diseases, but the decline is steady and cumulative. Most people lose roughly 4% of their muscle strength per year, and functional ability on standardized rating scales drops by about 6% annually. The disease unfolds over years, not months, but the gradual nature can make it harder to notice changes until a significant threshold is crossed.
Which Muscles Weaken First
IBM follows a fairly predictable pattern. The quadriceps (front of the thigh) and deep finger flexors (the muscles that let you grip and pinch) are almost always the first to go. Weakness in these areas is the hallmark of the disease, and it’s typically asymmetric, meaning one side weakens faster than the other. A useful clinical clue is that knee extension weakens more than hip flexion, and finger flexion weakens more than finger extension. In practical terms, you might notice trouble rising from a chair or climbing stairs before you notice problems walking on flat ground. Grip strength fades in ways that make turning keys, opening jars, or buttoning shirts increasingly difficult.
Pinch strength declines fastest of all, losing roughly 10% per year in longitudinal studies. Knee extension loses about 4% annually. These numbers vary from person to person, but the pattern is consistent: the muscles IBM targets first continue to deteriorate the fastest.
Milestones in Functional Decline
The timeline from symptom onset to major mobility changes follows a general arc. After an average disease duration of about 7 years, 56% of patients need some form of assistive device, whether a cane, walker, or brace. About 20% require a wheelchair or motorized scooter at that point. For those who do eventually become wheelchair-dependent, the median time from symptom onset is around 14 years.
These are averages, and individual trajectories vary considerably. Some people maintain independent walking for well over a decade, while others progress faster. Falls become a common and serious concern as quadriceps weakness advances. Surveys of people living with IBM show that falls happen frequently regardless of how long someone has had the disease, and they’re often poorly addressed with appropriate physical therapy or prevention strategies.
Swallowing Difficulties
Difficulty swallowing (dysphagia) is one of the most underrecognized complications of IBM. Estimates of how many people develop it range from 40% to 80%, depending on how carefully clinicians look for it. When patients are specifically asked about swallowing symptoms through detailed questionnaires, the number reaches 80%. When clinicians only check incidentally, the figure sits closer to 40%.
Dysphagia is generally considered a later complication, appearing after limb weakness is well established. But it doesn’t always follow that pattern. In some case series, swallowing problems were the very first symptom in 10% to 15% of patients, sometimes predating limb weakness by 5 to 10 years. This means it’s worth paying attention to subtle changes like food sticking in your throat, coughing during meals, or taking longer to eat, even early in the disease.
The Diagnostic Delay Problem
One complicating factor in understanding progression is that IBM is frequently misdiagnosed. The average time from first symptoms to an accurate diagnosis is about 3 years, and roughly 40% of patients receive an incorrect initial diagnosis. Many are first told they have polymyositis or another inflammatory myopathy, which leads to treatments that don’t work for IBM. This delay means that by the time someone receives the correct diagnosis, they may already be several years into the disease.
Impact on Life Expectancy
IBM has traditionally been considered a disease that doesn’t shorten life. More recent data tells a different story. A study published in Rheumatology found that 10-year survival from diagnosis was 36% for IBM patients, compared to 59% for age- and sex-matched people in the general population. On average, people with IBM died about 3 years younger than matched controls. The 5-year survival was 52%, compared to 81% in the general population.
These numbers reflect an older patient population (IBM typically begins after age 50), so some of the mortality relates to age and associated health conditions rather than the muscle disease alone. Still, the increased mortality risk is real and roughly 2.7 times higher than for matched controls.
Can Exercise Slow the Decline
There’s no drug that reliably slows IBM progression, but exercise appears to help preserve function. A randomized controlled trial of high-intensity resistance training in myositis patients found that 16 weeks of structured training improved quality of life, muscle strength, and muscle endurance. At one-year follow-up, muscle endurance gains persisted in the exercise group, with meaningful improvements in tasks like sit-to-stand repetitions, timed walking, and getting up from a chair.
Strength gains were harder to maintain. While the exercise group held onto improvements at one year compared to their own baseline, they were no longer statistically better than the control group for raw strength. Endurance, however, remained significantly better. This suggests that continued, structured exercise can help you function better in daily activities even if it can’t fully counteract the underlying muscle loss. The key word is “continued”: when exercise stopped, the benefits began to erode within months.
What the Overall Trajectory Looks Like
Using the IBM Functional Rating Scale (IBMFRS), which scores everyday abilities like swallowing, handwriting, cutting food, and walking, patients in one international registry dropped from an average score of about 28 out of 40 to roughly 24 over two years. That’s a loss of about 2 points per year, each point representing a noticeable change in one daily activity.
The overall picture is one of slow but relentless decline. Year to year, changes can feel subtle. But over 5 to 10 years, the cumulative effect transforms daily life. Activities that require strong grip or stable knees become progressively harder: getting out of a car, walking on uneven ground, opening containers, handwriting. Most people develop strategies and adaptations along the way, and assistive devices can extend independence significantly. The disease is not rapidly fatal, but it does reshape what daily life looks like over the course of a decade or more.